FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034243214> ?p ?o ?g. }

• W2034243214 endingPage "1489" @default.
• W2034243214 startingPage "1480" @default.
• W2034243214 abstract "Context: Acute asthma causes nearly 2 million hospital emergency department (ED) visits in the United States annually, and hospitalization after an ED visit and relapse after ED discharge are common. Objective: To evaluate the adding of therapy with zafirlukast to standardized care for patients with acute asthma in the ED and a 28-day follow-up period. Design and patients: A total of 641 patients presenting to the ED with acute asthma were randomized to receive either single-dose zafirlukast, 160 mg (Z160) [162 patients], zafirlukast, 20 mg (Z20) [158 patients]), or placebo (321 patients) as adjunct treatment to standard care in this double-blind, multicenter trial. Assessments, including spirometry and symptom scores, were obtained before each albuterol treatment and at 4 h. Patients who were discharged from the ED after 4 h continued outpatient therapy over a 28-day period and received either Z20 bid (276 patients) or placebo (270 patients) in addition to prednisone, albuterol, and their previous asthma medications. FEV1 was measured at clinic visits on days 10 and 28. Patients recorded outpatient clinical data twice daily on a home diary card. Main outcome measures: the effect of zafirlukast on relapse after ED discharge. Other assessments were the rate of extended care (ie, ED stay for > 4 h or hospitalization), FEV1, and symptoms. Results: At the end of the outpatient period, 65 of 276 patients (23.6%) treated with zafirlukast and 78 of 270 patients (28.9%) treated with placebo relapsed (p = 0.047; absolute reduction, 5.3%; relative reduction, 18.3%). At the end of the ED period, 16 of 162 patients (9.9%) treated with Z160, 26 of 158 patients (16.5%) treated with Z20, and 48 of 321 patients (15.0%) treated with placebo required extended care (p = 0.052; absolute reduction with Z160 compared to placebo, 5.1%; relative reduction, 34%). These findings were supported by a significant improvement in FEV1 and dyspnea in the ED with the use of Z160 therapy, and by greater improvement in FEV1 and symptoms during the outpatient period for patients treated with Z20. Conclusions: When added to standardized care, therapy with Z20 bid reduced the risk of relapse compared with placebo over a 28-day treatment period. One dose of Z160 in the ED also reduced the rate of extended care. Acute asthma causes nearly 2 million hospital emergency department (ED) visits in the United States annually, and hospitalization after an ED visit and relapse after ED discharge are common. To evaluate the adding of therapy with zafirlukast to standardized care for patients with acute asthma in the ED and a 28-day follow-up period. A total of 641 patients presenting to the ED with acute asthma were randomized to receive either single-dose zafirlukast, 160 mg (Z160) [162 patients], zafirlukast, 20 mg (Z20) [158 patients]), or placebo (321 patients) as adjunct treatment to standard care in this double-blind, multicenter trial. Assessments, including spirometry and symptom scores, were obtained before each albuterol treatment and at 4 h. Patients who were discharged from the ED after 4 h continued outpatient therapy over a 28-day period and received either Z20 bid (276 patients) or placebo (270 patients) in addition to prednisone, albuterol, and their previous asthma medications. FEV1 was measured at clinic visits on days 10 and 28. Patients recorded outpatient clinical data twice daily on a home diary card. the effect of zafirlukast on relapse after ED discharge. Other assessments were the rate of extended care (ie, ED stay for > 4 h or hospitalization), FEV1, and symptoms. At the end of the outpatient period, 65 of 276 patients (23.6%) treated with zafirlukast and 78 of 270 patients (28.9%) treated with placebo relapsed (p = 0.047; absolute reduction, 5.3%; relative reduction, 18.3%). At the end of the ED period, 16 of 162 patients (9.9%) treated with Z160, 26 of 158 patients (16.5%) treated with Z20, and 48 of 321 patients (15.0%) treated with placebo required extended care (p = 0.052; absolute reduction with Z160 compared to placebo, 5.1%; relative reduction, 34%). These findings were supported by a significant improvement in FEV1 and dyspnea in the ED with the use of Z160 therapy, and by greater improvement in FEV1 and symptoms during the outpatient period for patients treated with Z20. When added to standardized care, therapy with Z20 bid reduced the risk of relapse compared with placebo over a 28-day treatment period. One dose of Z160 in the ED also reduced the rate of extended care." @default.
• W2034243214 created "2016-06-24" @default.
• W2034243214 creator A5020393038 @default.
• W2034243214 creator A5024466535 @default.
• W2034243214 creator A5033595975 @default.
• W2034243214 creator A5045133348 @default.
• W2034243214 creator A5070351059 @default.
• W2034243214 creator A5077622042 @default.
• W2034243214 creator A5079044018 @default.
• W2034243214 creator A5083247932 @default.
• W2034243214 date "2004-11-01" @default.
• W2034243214 modified "2023-09-29" @default.
• W2034243214 title "Zafirlukast Treatment for Acute Asthma" @default.
• W2034243214 cites W1482789289 @default.
• W2034243214 cites W1968945837 @default.
• W2034243214 cites W1971569966 @default.
• W2034243214 cites W1988831361 @default.
• W2034243214 cites W1994111044 @default.
• W2034243214 cites W1996982788 @default.
• W2034243214 cites W2004008756 @default.
• W2034243214 cites W2006300452 @default.
• W2034243214 cites W2008660872 @default.
• W2034243214 cites W2014608611 @default.
• W2034243214 cites W2017805361 @default.
• W2034243214 cites W2022724314 @default.
• W2034243214 cites W2026435977 @default.
• W2034243214 cites W2027289127 @default.
• W2034243214 cites W2043158492 @default.
• W2034243214 cites W2057290660 @default.
• W2034243214 cites W2065283934 @default.
• W2034243214 cites W2072795507 @default.
• W2034243214 cites W2082638352 @default.
• W2034243214 cites W2097832038 @default.
• W2034243214 cites W2099665268 @default.
• W2034243214 cites W2109336936 @default.
• W2034243214 cites W2112718944 @default.
• W2034243214 cites W2113003679 @default.
• W2034243214 cites W2123531714 @default.
• W2034243214 cites W2135605030 @default.
• W2034243214 cites W2136210090 @default.
• W2034243214 cites W2137607488 @default.
• W2034243214 cites W2138466059 @default.
• W2034243214 cites W2139054312 @default.
• W2034243214 cites W2145366998 @default.
• W2034243214 cites W2147170492 @default.
• W2034243214 cites W2149524195 @default.
• W2034243214 cites W2604596332 @default.
• W2034243214 doi "https://doi.org/10.1378/chest.126.5.1480" @default.
• W2034243214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15539716" @default.
• W2034243214 hasPublicationYear "2004" @default.
• W2034243214 type Work @default.
• W2034243214 sameAs 2034243214 @default.
• W2034243214 citedByCount "74" @default.
• W2034243214 countsByYear W20342432142012 @default.
• W2034243214 countsByYear W20342432142013 @default.
• W2034243214 countsByYear W20342432142014 @default.
• W2034243214 countsByYear W20342432142015 @default.
• W2034243214 countsByYear W20342432142016 @default.
• W2034243214 countsByYear W20342432142017 @default.
• W2034243214 countsByYear W20342432142019 @default.
• W2034243214 countsByYear W20342432142021 @default.
• W2034243214 countsByYear W20342432142022 @default.
• W2034243214 crossrefType "journal-article" @default.
• W2034243214 hasAuthorship W2034243214A5020393038 @default.
• W2034243214 hasAuthorship W2034243214A5024466535 @default.
• W2034243214 hasAuthorship W2034243214A5033595975 @default.
• W2034243214 hasAuthorship W2034243214A5045133348 @default.
• W2034243214 hasAuthorship W2034243214A5070351059 @default.
• W2034243214 hasAuthorship W2034243214A5077622042 @default.
• W2034243214 hasAuthorship W2034243214A5079044018 @default.
• W2034243214 hasAuthorship W2034243214A5083247932 @default.
• W2034243214 hasConcept C118552586 @default.
• W2034243214 hasConcept C126322002 @default.
• W2034243214 hasConcept C142724271 @default.
• W2034243214 hasConcept C151730666 @default.
• W2034243214 hasConcept C204787440 @default.
• W2034243214 hasConcept C27081682 @default.
• W2034243214 hasConcept C2776042228 @default.
• W2034243214 hasConcept C2776452501 @default.
• W2034243214 hasConcept C2779343474 @default.
• W2034243214 hasConcept C2780724011 @default.
• W2034243214 hasConcept C2780815506 @default.
• W2034243214 hasConcept C2910384678 @default.
• W2034243214 hasConcept C512399662 @default.
• W2034243214 hasConcept C71924100 @default.
• W2034243214 hasConcept C86803240 @default.
• W2034243214 hasConceptScore W2034243214C118552586 @default.
• W2034243214 hasConceptScore W2034243214C126322002 @default.
• W2034243214 hasConceptScore W2034243214C142724271 @default.
• W2034243214 hasConceptScore W2034243214C151730666 @default.
• W2034243214 hasConceptScore W2034243214C204787440 @default.
• W2034243214 hasConceptScore W2034243214C27081682 @default.
• W2034243214 hasConceptScore W2034243214C2776042228 @default.
• W2034243214 hasConceptScore W2034243214C2776452501 @default.
• W2034243214 hasConceptScore W2034243214C2779343474 @default.
• W2034243214 hasConceptScore W2034243214C2780724011 @default.
• W2034243214 hasConceptScore W2034243214C2780815506 @default.
• W2034243214 hasConceptScore W2034243214C2910384678 @default.

• next